Biologic treatments for psoriasis have different anatomical specificities in residual PASI
JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2026
DOI: 10.1111/ddg.15924 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2026. Verfasst von Martina Burlando und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinica Dermatologica, DissaL, Università di Genova, Ospedale Policlinico San Martino - IRCCS, Genova, Italy. Hauptthemen laut MEDLINE: Psoriasis, Biological Products. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and objectives Improved understanding of the immunopathogenesis of psoriasis has led to the development of effective targeted therapies, but patients who respond to treatment without total skin clearance have residual disease. The aim of this study was to demonstrate the existence of specific residual disease (or residual PASI) anatomical localizations related to different biologic agents. Methods and patients This retrospective, observational, multi‐center study analyzed clinical data of patients affected by psoriasis who had received biologic treatments for at least 6 months. The data analysis focused on patients with residual PASI.
Results
A total of 228 of 1,000 patients showed residual disease despite achieving PASI 90 at weeks 24–28 of biologic treatment. The anatomical sites most frequently involved in residual disease were the lower limbs (44.3%). We observed differences among the biologic agents in terms of frequency and localization of residual disease. The localization of residual skin lesions to lower limbs was associated with treatment switching/interruption. The drugs with the highest and lowest proportion of patients with residual disease in the lower limbs were, respectively, secukinumab and risankizumab.
Conclusions
Treatment with anti‐IL‐17 and anti‐IL‐23 drugs is characterized by the persistence of residual skin lesions with differences in terms of frequency and anatomical localizations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinica Dermatologica, DissaL, Università di Genova, Ospedale Policlinico San Martino - IRCCS, Genova, Italy.
- Section of Biostatistics, Department of Health Sciences, University of Genova, Genova, Italy.
- Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy.
ORCID-Profile: Martina Burlando, Aurora Parodi, Ilaria Salvi
Zitieren
APA
Burlando, M., Schiavetti, I., Parodi, A., Cozzani, E., Mastorino, L., Bongiovanni, E., Salvi, I., Vecchio, M. D., & Dapavo, P. (2026). Biologic treatments for psoriasis have different anatomical specificities in residual PASI. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.15924
Vancouver
Burlando M, Schiavetti I, Parodi A, Cozzani E, Mastorino L, Bongiovanni E, et al. Biologic treatments for psoriasis have different anatomical specificities in residual PASI. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2026. doi:10.1111/ddg.15924
BibTeX
@article{Burlando2026,
author = {Burlando, Martina and Schiavetti, Irene and Parodi, Aurora and Cozzani, Emanuele and Mastorino, Luca and Bongiovanni, Eleonora and Salvi, Ilaria and Vecchio, Martina Del and Dapavo, Paolo},
title = {Biologic treatments for psoriasis have different anatomical specificities in residual PASI},
journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
year = {2026},
doi = {10.1111/ddg.15924}
}
EUVIMED